Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sihuan Pharmaceutical Holdings Group Ltd. has announced that its subsidiary, Honghe Pharmaceutical, received approval from China’s National Medical Products Administration for their Ticagrelor Orodispersible Tablet, a novel antithrombotic medication. This first domestic product approval marks a significant addition to the Group’s cardiovascular drug portfolio and is expected to positively impact its operating performance in a market exceeding RMB 10 billion in 2023.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.
